Rigel Pharmaceuticals

Rigel Pharmaceuticals

Quarterly Financials

Values in thousands2026-06-302026-03-312025-12-312025-09-30
Revenue
$78,703
$58,818
$69,802
$69,462
Gross Profit
70,178
54,212
63,847
64,709
EBITDA
25,212
13,687
25,014
30,117
EBIT
24,364
13,090
24,413
29,514
Net Income
17,290
8,654
268,065
27,900
Net Change In Cash
78,703
58,818
69,802
69,462
Free Cash Flow
30,653
2,725
21,992
24,019
Cash
60,816
24,411
40,580
48,534
Basic Shares
19,570
19,686
18,840
19,156

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$294,282
$179,278
$116,882
$120,242
Gross Profit
274,661
160,631
109,772
118,493
EBITDA
131,562
28,512
-16,981
-53,868
EBIT
129,147
26,284
-18,219
-54,866
Net Income
367,024
17,485
-25,091
-58,573
Net Change In Cash
294,282
179,278
116,882
120,242
Cost of Revenue
5,569
Free Cash Flow
75,655
31,075
-20,743
-74,208
Cash
40,580
56,746
32,786
24,459
Basic Shares
18,840
17,687
17,401
17,240

Earnings Calls

QuarterEPS
2026-06-30
$0.88
2026-03-31
$0.44
2025-12-31
$1.11
2025-09-30
$1.46